We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Should Athletes Be Screened for Sickle Cell Trait?

By LabMedica International staff writers
Posted on 21 Sep 2010
An extensive and high-profile screening program to test college athletes in the United States for the sickle cell anemia gene has evoked some controversy. More...


Starting this academic year, the [U.S.] National Collegiate Athletic Association (NCAA) plans to screen close to 167,000 college athletes for sickle cell trait. Students participating in athletics at Division I schools will be tested for the gene responsible for sickle cell disease. The program aims to identify carriers of a single sickle-cell gene--not those who carry two such genes, and have sickle-cell disease.

Those who inherit sickle-cell genes from both parents will have sickle-cell anemia, a chronic and painful disease in which red blood cells fail to carry oxygen efficiently to muscles and organs. However, those who carry a single gene have no outward symptoms of the genetic affliction, which mostly affects those of African descent.

Carriers of the sickle-cell gene are more prone than those without the gene to develop a potentially deadly muscle-wasting condition called rhabdomyolisis after intense physical exertion, as well blockages in blood vessels carrying oxygen to the spleen (especially when exercising at high altitudes).

The proposed [U.S.] National Collegiate Athletic Association (NCAA) screening is expected to identify 400 to 500 carriers each year. Eight percent of African-Americans carry at least a single sickle-cell gene (rates among Latinos and white Americans are .08% and .02% respectively).

In a commentary published in the September 9, 2010, New England Journal of Medicine (NEJM), attorney Vence L. Bonham and scientist Lawrence C. Brody of the [U.S.] National Human Genome Research Institute (NHGRI; Bethesda, MD, USA), and Johns Hopkins Children's Center (Baltimore, MD, USA) pediatrician George Dover noted that the NCAA has failed to put in place measures that protect athletes identified as carriers from stigma or discrimination. Nor have they arranged counseling on what their status means (and does not mean), and how they might protect themselves from the risks that come with it. They warned that the sickle cell testing "may also open the door to additional testing."

The commentary adds that because the tests will take place outside of a patient-physician relationship, athletes will lack confidentiality. The authors noted that for students on athletic scholarships, such testing could be viewed as coercive. In addition, they questioned why the program appears limited only to Division I schools. "Are athletes in NCAA Divisions II and III at less risk, and if not, why are they exempt from testing?"

However, the NCAA fact sheet about sickle cell trait testing states that athletes with sickle cell trait should not be excluded from participation as precautions can be put into place. Most U.S. states test at birth, but most athletes with sickle cell trait do not know they have it.

The NCAA recommends that athletics departments confirm the sickle cell trait status in all student-athletes. Knowledge of sickle cell trait status can be a gateway to education and simple precautions that may prevent collapse among athletes with the trait, allowing them to succeed in their sport.

A growing number of tests--medical and genetic--are becoming available to identify persons at particular risk of disease or injury. As employers and league officials embrace those tests to protect themselves and their members, they may look to the NCAA's new initiative.

Related Links:

[U.S.] National Collegiate Athletic Association
[U.S.] National Human Genome Research Institute
Johns Hopkins Children's Center




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.